Y-Intercept (HK)’s Cue Biopharma CUE Stock Holding History

Y-Intercept (HK)’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,121	Closed	-$191K	–	1397
2024 Q2	$191K	Buy	+5,121	New	+$253K	0.01%	1184

Other funds holding CUE

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

GLA

Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Y-Intercept (HK)'s CUE Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Cue Biopharma (CUE) in Q3 2024, closing a stake of 5,121 shares — an estimated $191K sold.

Y-Intercept (HK) first reported a position in CUE in Q2 2024 and held it in 1 quarter. The position peaked at $191K in Q2 2024. 50 funds tracked by Wall St. Rank hold CUE as of Q3 2024.

Y-Intercept (HK) reported no remaining Cue Biopharma position as of Q3 2024 after selling out during the quarter.
Y-Intercept (HK) sold 5,121 Cue Biopharma shares in Q3 2024, an estimated $191K.
Y-Intercept (HK) first reported a position in Cue Biopharma in Q2 2024 and held it in 1 quarter.
Y-Intercept (HK)'s Cue Biopharma position peaked at $191K in Q2 2024.
50 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.